AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20089774
Drug: Lactobacillus salivarius
RxNorm normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus salivarius CUL61 and Lactobacillus paracasei CUL08 and Bifidobacterium animalis subsp. lactis CUL34 and Bifidobacterium bifidum CUL20; 1 x 10(10) colony-forming units administered daily during the last month of pregnancy and to infants aged 0-6 months.
Trial: 17697906
Drug: ER oxycodone
RxNorm normalized name: oxycodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER oxycodone
Trial: 12188097
Drug: Naltrexone (NTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX), 50 mg/day
Trial: 10553752
Drug: D-serine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (30 mg/kg per day)
Trial: 6851723
Drug: Heparin-dihydergot 2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-dihydergot 2500 (2 X 2500 IU) with 0.5 mg dihydroergotamine (DHE)
Trial: 6851723
Drug: Conventional low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional low dose heparin regimen (2 X 5000 IU)
Trial: 26569165
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea beverages with low catechin content (149.5 mg catechins with a galloyl moiety)
Trial: 26569165
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea beverages with high catechin content (246.5 mg catechins with a galloyl moiety)
Trial: 25012418
Drug: SSRI (escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI (escitalopram or citalopram) or dual therapy (serotonergic agent)
Trial: 22398243
Drug: MVA-mBN32 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-mBN32 vaccine after first immunization
Trial: 22398243
Drug: MVA-mBN32 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-mBN32 vaccine after second immunization
Trial: 22398243
Drug: MVA-mBN32 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-mBN32 vaccine
Trial: 20104460
Drug: Milrinone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50 microg/kg bolus followed by 0.5 microg/kg/min infusion for 24 hours)
Trial: 16248851
Drug: Phenserine tartrate
RxNorm normalized name: chlorpheniramine
DrugBank: Phenserine (DB04892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenserine tartrate 10 mg
Trial: 16248851
Drug: Phenserine tartrate
RxNorm normalized name: chlorpheniramine
DrugBank: Phenserine (DB04892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenserine tartrate 5 mg
Trial: 16248851
Drug: Phenserine tartrate
RxNorm normalized name: chlorpheniramine
DrugBank: Phenserine (DB04892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenserine tartrate 20 mg
Trial: 12137863
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg daily on days 5‐9 after menses
Trial: 12137863
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg daily on days 5‐9 after menses
Trial: 7993190
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of recombinant human erythropoietin (rhEPO) at a median dose of 33 U/kg body weight three times a week
Trial: 7993190
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of recombinant human erythropoietin (rhEPO) at a median dose of 22 U/kg body weight
Trial: 7993190
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of rhEPO
Trial: 7993190
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of rhEPO
Trial: 178197
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of glucagon
Trial: 6783023
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (1200 mg daily for one week)
Trial: 30007519
Drug: Automated VR
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated VR treatment (delivered in roughly six 30‐min sessions over a 2‐week period)
Trial: 26518514
Drug: 1250 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg/day omega‐3 fatty acid + vitamin E placebo
Trial: 26518514
Drug: 1250 mg
RxNorm normalized name: bran 1250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg omega‐3 fatty acids/day + 400 IU/day vitamin E
Trial: 24999060
Drug: Long-term medication
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term medication assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX)
Trial: 24999060
Drug: Short-term medication
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term medication assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX)
Trial: 22836073
Drug: Rosuvastatin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 80 mg once weekly
Trial: 20598959
Drug: US-guided pes
RxNorm normalized name: Ipomoea pes-caprae flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided pes anserinus bursa injections
Trial: 20598959
Drug: Unguided pes
RxNorm normalized name: Ipomoea pes-caprae flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided pes anserinus bursa injections
Trial: 12411528
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (CCB), amlodipine, administered for 7 days prior to and for 7 days following the damage protocol
Trial: 12411528
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (CCB), amlodipine
Trial: 7860392
Drug: Interdigitating chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdigitating chemotherapy and radiotherapy (COPE followed by thoracic radiation therapy)
Trial: 7860392
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and radiotherapy (DDP and etoposide with concurrent thoracic radiation therapy)
Trial: 7860392
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) after completion of chemotherapy
Trial: 31903865
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone treatment in euthyroid women with thyroid autoimmunity
Trial: 31903865
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone treatment for TSH >4 mIU/L
Trial: 30740877
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin 2% powder spray
Trial: 30049503
Drug: Morphine ARER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine ARER 100 mg
Trial: 30049503
Drug: Extended-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release morphine 100 mg
Trial: 21558456
Drug: Saquinavir-boosted ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir-boosted ritonavir at therapeutic dose (1000/100 mg bid)
Trial: 21558456
Drug: Saquinavir-boosted ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir-boosted ritonavir at supratherapeutic dose (1500/100 mg bid)
Trial: 21558456
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (moxifloxacin 400 mg)
Trial: 17531335
Drug: Combined schedule
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined schedule of external beam treatment (35.75 Gy in 13 fractions) followed by high dose rate brachytherapy (17 Gy in two fractions)
Trial: 16366808
Drug: Brief Relationship
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Relationship Therapy (BRT)
Trial: 16366808
Drug: Standard Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Behavioral Couples Therapy (S-BCT)
Trial: 16366808
Drug: Psychoeducational Attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Psychoeducational Attention Control Treatment (PACT)
Trial: 10418023
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefepime (Group 1, n = 9)
Trial: 10418023
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of cefepime (Group 2, n = 9)
Trial: 7739307
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin infusion (partial thromboplastin time 1.5‐2 times baseline)
Trial: 7739307
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (adjusted dose with partial thromboplastin time 1.5‐2 times baseline)
Trial: 2298592
Drug: 200 or
RxNorm normalized name: Mag-200 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 or 400 ml ice water ingestion
Trial: 24886235
Drug: STAIR Narrative
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAIR Narrative Therapy
Trial: 18579575
Drug: Long-term antidepressant
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antidepressant medication in patients with MDD
Trial: 18579575
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of citalopram to controls
Trial: 9927101
Drug: 5-mg pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg pilocarpine tablets (20 mg/d)
Trial: 9927101
Drug: 2.5-mg pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-mg pilocarpine tablets
Trial: 7752293
Drug: Therapy coupled
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy coupled with urine monitoring
Trial: 2196772
Drug: DL‐diltiazem (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL‐diltiazem (0.4 mg/kg as a bolus intravenously, followed by an infusion of 15 mg/hr)
Trial: 31529059
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg Synacthen
Trial: 29753264
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg dexamethasone
Trial: 22101218
Drug: Self-Administered Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Administered Therapy (SAT)
Trial: 23768797
Drug: BodiMojo intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BodiMojo intervention for four weekly health class periods
Trial: 15315844
Drug: Modified WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified WHO regimen (Rifampicin 600 mg once a month supervised, 50 mg of Clofazimine and 100 mg of Dapsone daily unsupervised) and BCG 0.1 mg per dose 6 monthly
Trial: 15315844
Drug: Multi-drug treatment
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug treatment (MDT) and Mw (2 x 10(8) killed bacilli per dose) 6 monthly
Trial: 15315844
Drug: Multi-drug treatment
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug treatment (MDT) with 0.1 ml of distilled water 6 monthly (control group)
Trial: 15315844
Drug: Both immunotherapy
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both immunotherapy groups (groups I and II)
Trial: 15315844
Drug: Immunotherapy groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy groups (groups I and II)
Trial: 8040775
Drug: Vancomycin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (25 micrograms/ml)
Trial: 2647033
Drug: Cotazym‐S‐Forte (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotazym‐S‐Forte (10,000 BP units of lipase activity per capsule)
Trial: 2647033
Drug: Pancrease (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrease (5000 BP units of lipase activity per capsule)
Trial: 20668324
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 2.4 g/day for 2 years
Trial: 16614398
Drug: EGG (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGG (640 mg/d additional dietary cholesterol and 600 microg lutein + zeaxanthin)
Trial: 16614398
Drug: SUB (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUB (0 mg/d cholesterol, 0 microg lutein + zeaxanthin)
Trial: 14714357
Drug: Puerarin Injection
RxNorm normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin Injection (PI) 200 ml by intravenous dripping once a day, starting one week before operation.
Trial: 14714357
Drug: Puerarin Injection
RxNorm normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin Injection (PI)
Trial: 10810000
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of oral antivitamin K therapy
Trial: 10810000
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of oral antivitamin K therapy
Trial: 8908224
Drug: Morphine IW,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine IW, saline IM
Trial: 8908224
Drug: Saline IW,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IW, morphine IM
Trial: 1920184
Drug: five-week daily
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: five-week daily exercise training
Trial: 1920184
Drug: exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise training including six sessions of relaxation therapy
Trial: 27299516
Drug: Systemic-behavioral treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic-behavioral treatment modules of the SELBST program
Trial: 23289958
Drug: CoQ10 200
RxNorm normalized name: CoQ10 200mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 200 mg d(‐1) for 3 months
Trial: 22522761
Drug: Pretransplant donor-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretransplant donor-specific antibodies
Trial: 22522761
Drug: Non-donor-specific antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-donor-specific antibodies
Trial: 22522761
Drug: Posttransplant donor-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant donor-specific antibodies
Trial: 11842916
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg Ginkgo biloba/Panax ginseng combination
Trial: 11842916
Drug: 640 mg
RxNorm normalized name: glycerin 1640 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 mg Ginkgo biloba/Panax ginseng combination
Trial: 11842916
Drug: 960 mg
RxNorm normalized name: glycerin 960 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg Ginkgo biloba/Panax ginseng combination
Trial: 7846134
Drug: Continuous-wave ultrasound
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-wave ultrasound at a dosage of 1.5 W/cm2 for 5 minutes
Trial: 2689046
Drug: Carteolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol (20 mg daily)
Trial: 28645475
Drug: Melatonin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (intravenous and intracoronary bolus)
Trial: 16971295
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy for Adherence to Antiretroviral Treatment (STAART)
Trial: 27249080
Drug: Doxazosin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin XL (4 mg/d to 16 mg/d over 12 days)
Trial: 27249080
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched capsules)
Trial: 24504804
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 250 mg/day
Trial: 24504804
Drug: Meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg/day
Trial: 12375378
Drug: Daily self-observation
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-observation measure of parental disciplinary behavior (diary)
Trial: 8672315
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic alone (lignocaine 10 mg ml‐1 - bupivacaine 3.75 mg ml‐1)
Trial: 8672315
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic with adrenaline (5 micrograms ml‐1)
Trial: 8672315
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic with hyaluronidase (75 iu ml‐1)
Trial: 2104079
Drug: Oral tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tobramycin
Trial: 31189519
Drug: IDegLira (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegLira (insulin degludec plus liraglutide)
Trial: 31189519
Drug: IGlar U100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGlar U100 (insulin glargine 100 units/mL)
Trial: 28332372
Drug: Aceclofenac controlled
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac controlled release (CR) 200 mg once daily
Trial: 19890073
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (STS) 3 mg/24 h
Trial: 19890073
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (STS) 6 mg/24 h
Trial: 15542048
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol treatment (1 mg 17-beta-estradiol + 1 mg drosperinone or 2 mg drosperinone or 3 mg drosperinone)
Trial: 15542048
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol treatment (45 microg 17-beta-estradiol + 30 microg levonorgestrel or 40 microg levonorgestrel)
Trial: 15542048
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and transdermal estradiol therapy
Trial: 10235427
Drug: Napsagatran 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napsagatran 5 mg/h
Trial: 10235427
Drug: Napsagatran 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napsagatran 9 mg/h
Trial: 9308743
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (control)
Trial: 8315426
Drug: Continuous bladder
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bladder irrigation with 200 mL/h of normal saline
Trial: 8315426
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion mesna at 100% of the cyclophosphamide dose
Trial: 27135916
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10(9) CFU/g each) for 8 weeks
Trial: 27135916
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose capsules) for 8 weeks